Prognostic groups according to the combined BCL2 IHC score and MYC deregulation status. (A) Prognostic group classification according to the BCL2 IHC score and MYC deregulation status. Group I (n = 124) had a BCL2 score of 0 to 2+ and non-MYC–deregulated DLBCL or a BCL2 score of 0 to 1+ and MYC-deregulated DLBCL; group II (n = 71) had a BCL2 score of 3+ and non-MYC–deregulated DLBCL or a BCL2 score of 2+ and MYC-deregulated DLBCL; and group III (n = 23) had a BCL2 score of 3+ and MYC-deregulated DLBCL. (B) Percentage of 3-year PFS rate of the various groups. (C-D) PFS and OS curves of patients with DLBCL treated with R-CHOP according to the prognostic groups. (E-F) PFS and OS curves of patients with DLBCL treated with R-CHOP according to the prognostic groups in the validation set.